These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 28890184)

  • 1. Evaluation of the Tumor Response After Neoadjuvant Chemotherapy in Breast Cancer Patients: Correlation Between Dynamic Contrast-enhanced Magnetic Resonance Imaging and Pathologic Tumor Cellularity.
    Choi WJ; Kim WK; Shin HJ; Cha JH; Chae EY; Kim HH
    Clin Breast Cancer; 2018 Feb; 18(1):e115-e121. PubMed ID: 28890184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of MRI and PET/CT after neoadjuvant chemotherapy in breast cancer patients: correlation with pathological response grading system based on tumor cellularity.
    Kim T; Kang DK; An YS; Yim H; Jung YS; Kim KS; Kang SY; Kim TH
    Acta Radiol; 2014 May; 55(4):399-408. PubMed ID: 23963151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Pathologic Response Evaluation Systems After Neoadjuvant Chemotherapy in Breast Cancers: Correlation With Computer-Aided Diagnosis of MRI Features.
    Choi WJ; Kim HH; Cha JH; Shin HJ; Chae EY
    AJR Am J Roentgenol; 2019 Oct; 213(4):944-952. PubMed ID: 31237439
    [No Abstract]   [Full Text] [Related]  

  • 4. Breast cancer: early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging.
    Cho N; Im SA; Park IA; Lee KH; Li M; Han W; Noh DY; Moon WK
    Radiology; 2014 Aug; 272(2):385-96. PubMed ID: 24738612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative evaluation of breast cancer response to neoadjuvant chemotherapy by diffusion tensor imaging: Initial results.
    Furman-Haran E; Nissan N; Ricart-Selma V; Martinez-Rubio C; Degani H; Camps-Herrero J
    J Magn Reson Imaging; 2018 Apr; 47(4):1080-1090. PubMed ID: 28901594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival outcomes of breast cancer patients who receive neoadjuvant chemotherapy: association with dynamic contrast-enhanced MR imaging with computer-aided evaluation.
    Yi A; Cho N; Im SA; Chang JM; Kim SJ; Moon HG; Han W; Park IA; Noh DY; Moon WK
    Radiology; 2013 Sep; 268(3):662-72. PubMed ID: 23592770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of pathological response to neoadjuvant chemotherapy in breast cancer patients by imaging.
    Kaise H; Shimizu F; Akazawa K; Hasegawa Y; Horiguchi J; Miura D; Kohno N; Ishikawa T
    J Surg Res; 2018 May; 225():175-180. PubMed ID: 29605029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Prediction of Response to Neoadjuvant Chemotherapy Using Dynamic Contrast-Enhanced MRI and Ultrasound in Breast Cancer.
    Kim Y; Kim SH; Song BJ; Kang BJ; Yim KI; Lee A; Nam Y
    Korean J Radiol; 2018; 19(4):682-691. PubMed ID: 29962874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic resonance imaging patterns of tumor regression after neoadjuvant chemotherapy in breast cancer patients: correlation with pathological response grading system based on tumor cellularity.
    Kim TH; Kang DK; Yim H; Jung YS; Kim KS; Kang SY
    J Comput Assist Tomogr; 2012; 36(2):200-6. PubMed ID: 22446360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
    Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
    Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI Volume Changes of Axillary Lymph Nodes as Predictor of Pathologic Complete Responses to Neoadjuvant Chemotherapy in Breast Cancer.
    Cattell RF; Kang JJ; Ren T; Huang PB; Muttreja A; Dacosta S; Li H; Baer L; Clouston S; Palermo R; Fisher P; Bernstein C; Cohen JA; Duong TQ
    Clin Breast Cancer; 2020 Feb; 20(1):68-79.e1. PubMed ID: 31327729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer.
    Goorts B; Dreuning KMA; Houwers JB; Kooreman LFS; Boerma EG; Mann RM; Lobbes MBI; Smidt ML
    Breast Cancer Res; 2018 Apr; 20(1):34. PubMed ID: 29669584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy.
    Li SP; Taylor NJ; Makris A; Ah-See ML; Beresford MJ; Stirling JJ; d'Arcy JA; Collins DJ; Padhani AR
    Radiology; 2010 Dec; 257(3):643-52. PubMed ID: 20858850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive Clinicopathologic and Dynamic Contrast-Enhanced MRI Findings for Tumor Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Eom HJ; Cha JH; Choi WJ; Chae EY; Shin HJ; Kim HH
    AJR Am J Roentgenol; 2017 Jun; 208(6):W225-W230. PubMed ID: 28350486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance imaging evaluation of residual tumors in breast cancer after neoadjuvant chemotherapy: surgical implications.
    Zhou J; Li G; Sheng F; Qiao P; Zhang H; Xing X
    Acta Radiol; 2016 May; 57(5):529-37. PubMed ID: 26231950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumor partitioning and texture analysis of dynamic contrast-enhanced (DCE)-MRI identifies relevant tumor subregions to predict pathological response of breast cancer to neoadjuvant chemotherapy.
    Wu J; Gong G; Cui Y; Li R
    J Magn Reson Imaging; 2016 Nov; 44(5):1107-1115. PubMed ID: 27080586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype.
    Namura M; Tsunoda H; Yagata H; Hayashi N; Yoshida A; Morishita E; Takei J; Suzuki K; Yamauchi H
    Clin Breast Cancer; 2018 Apr; 18(2):128-134. PubMed ID: 28843513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective factors to raise diagnostic performance of breast MRI for diagnosing pathologic complete response in breast cancer patients after neoadjuvant chemotherapy.
    Choi BB; Kim SH
    Acta Radiol; 2015 Jul; 56(7):790-7. PubMed ID: 24951616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigating the prediction value of multiparametric magnetic resonance imaging at 3 T in response to neoadjuvant chemotherapy in breast cancer.
    Minarikova L; Bogner W; Pinker K; Valkovič L; Zaric O; Bago-Horvath Z; Bartsch R; Helbich TH; Trattnig S; Gruber S
    Eur Radiol; 2017 May; 27(5):1901-1911. PubMed ID: 27651141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.
    Charehbili A; Wasser MN; Smit VT; Putter H; van Leeuwen-Stok AE; Meershoek-Klein Kranenbarg WM; Liefers GJ; van de Velde CJ; Nortier JW; Kroep JR
    Eur J Surg Oncol; 2014 Oct; 40(10):1216-21. PubMed ID: 25150151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.